Fimasartan (BR-A-657) Single Oral Dose in Healthy Subjects

NCT01289886 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2011-02-04

No results posted yet for this study

Summary

The objective of this study is to determine the safety and tolerability and to determine the Pharmacokinetic and Pharmacodynamic (PK/PD) of ascending single oral dose of BR-A-657 in healthy male subjects.

Conditions

  • Essential Hypertension

Interventions

DRUG

BR-A-657

20, 60, 120, 240, 360, 480mg or placebo tablet

Sponsors & Collaborators

  • Covance

    collaborator INDUSTRY
  • Boryung Pharmaceutical Co., Ltd

    lead INDUSTRY

Principal Investigators

  • E Engmann, MB ChB · Covance Clinical Research Unit

Study Design

Allocation
RANDOMIZED
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2003-09-30
Primary Completion
2003-11-30
Completion
2003-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01289886 on ClinicalTrials.gov